ST6GALNAC2

Across TCGA pan-cancer cohorts, ST6GALNAC2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ST6GALNAC2 data layer compared with 23 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in sarcoma (SARC), where higher ST6GALNAC2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ST6GALNAC2 expression acts as an unfavorable survival marker.

SARC, BLCA, and HNSC are the cancer types where ST6GALNAC2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SARC	OS	Median	All	0.022	0.861	<.001	12	view →
BLCA	OS	Median	III,IV	0.183	0.684	.004	9	view →
HNSC	OS	Median	II,III,IV	0.214	0.600	.041	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ST6GALNAC2–SARC (OS)

Open the SARC breakdown →